On the heels of the premiere of its first-ever Spanish-language Cologuard campaign, Exact Sciences is doubling down on its ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

For colorectal cancer screening, colonoscopy and stool tests are more effective and less costly than novel first-generation ...

Last month, Exact Sciences secured FDA’s approval for its Cologuard Plus test, approved for adults ages 45 and above who are at average risk for colorectal cancer (CRC). The approval is based on the ...

New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung ...

Against the backdrop of high medical costs and an imbalance of access to care, is there reason to be optimistic about the ...

At the beginning of October, the FDA approved the Cologuard Plus test, a next-generation, multitarget stool DNA test. While fecal testing is a good option for some patients, colonoscopy remains the ...

At the beginning of October, the FDA approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. In a trial of ...

The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers ...

Amalgamated Bank reduced its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.8% in the 3rd quarter, ...

Tucson, Ariz. (November 14, 2024) – The Tucson Conquistadores and the Cologuard Classic by Exact Sciences will host a two-night Concert Series Presented by Kaiser Garage Doors & Gates, IBM and ...

Exact Sciences' partnership with Ponce will help raise awareness among Hispanic adults about the importance of early detection through regular colon cancer screening, with the Cologuard ® test as a ...